

Novel Non-Covalent BTK Inhibitor, Exhibits Potent Anti-tumor Activity in B-Cell Lymphoma



ONCOLOGY	Candidate
Product Type	Small molecule inhibitor
Indication	B cell Lymphoma
Target	Bruton's tyrosine kinase (BTK)
MoA(Mechanism of Action)	Inhibition of BTK wild type & BTK C481 mutation
Competitiveness	Best-in-class non-covalent BTK inhibitor In combination with Venetoclax, SRT135 effectively induces apoptosis in B cell lymphoma cells
Development Stage	Lead Optimization (Lead to Candidate)
Route of Administration	Oral